EMD Millipore, iPS Academia Japan sign licensing agreement
EMD Millipore and iPS Academia Japan Inc. (AJ) announced a global licensing agreement for AJ's induced pluripotent stem (iPS) cell patent portfolio. The non-exclusive agreement provides EMD Millipore the opportunity to continue to develop and ultimately commercialize iPS cells for research applications. Under the agreement, EMD Millipore will continue to offer its STEMCCA reprogramming kits, which provide a highly efficient, reproducible method for creating iPS cells. The iPS cell patent portfolio is a result of work by Professor Shinya Yamanaka, MD, PhD, Center for iPS Cell Research and Application at Kyoto University, Japan. Terms of the agreement are not disclosed.
Induced pluripotent stem (iPS) cells, discovered by Yamanaka, are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Induced pluripotent stem (iPS) cells have potential to further various aspects of stem cell research, from the establishment of patient-specific stem cell populations to disease models.
EMD Millipore's STEMCCA kit is designed for researchers to obtain and work with induced pluripotent stem (iPS) cells. Using the STEMCCA kit, scientists are able to generate human and mouse iPS cells using a single, excisable polycistroniclentiviral vector that delivers all four reprogramming factors discovered by Yamanaka.Source: EMD Millipore